Last Updated: Thursday, August 01, 2024
The Hemophilia and Bleeding Disorder Drug Program is only applicable to Delaware, Pennsylvania, and West Virginia.
Managing hemophilia and bleeding disorders is a complex process involving a rigorous and expensive regimen of specialty drugs. The high cost of these drugs can be a key barrier to care for patients with these conditions.
Highmark is taking action to help manage the cost of these drugs through the hemophilia and bleeding disorder drug program.
Exclusive Specialty providers for this program include:
These providers have access to all hemophilia drugs and ability to treat members in all states. These are self-administered drugs, so there is no need for member coordination in terms of physical locations where these drugs are obtained.
Historically, Highmark had covered hemophilia and bleeding disorder drugs under members’ medical benefits.
On January 1, 2020, Highmark shifted hemophilia and bleeding disorder drugs under members’ pharmacy benefits because these drugs are self-administered and more appropriate for the pharmacy benefit.
Contact the specialty pharmacies at the following numbers:
For general questions, contact:
Related Links
Additional information on Prescription Drug Programs can be found in the Highmark Provider Manual - Chapter 4, Unit 6.